{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:45:15Z","timestamp":1778568315258,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09303-0","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T12:02:01Z","timestamp":1709985721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term antigen-specific immune response by an oncolytic adenovirus encoding SP-SA-E7-4-1BBL in HPV-16 cancer model"],"prefix":"10.1007","volume":"51","author":[{"given":"Alejandra G.","family":"Martinez-Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Garza-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria de J.","family":"Loera-Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila A.","family":"Villa-Cedillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aracely","family":"Garcia-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humberto","family":"Rodriguez-Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando E.","family":"Flores-Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Valdes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-6155","authenticated-orcid":false,"given":"Jose J.","family":"Perez-Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odila","family":"Saucedo-Cardenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"key":"9303_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA: A Cancer J Clin"},{"key":"9303_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer Statistics, 2021. CA: A Cancer J Clin 71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA: A Cancer J Clin"},{"key":"9303_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102429","volume":"109","author":"N Sobhani","year":"2022","unstructured":"Sobhani N, Scaggiante B, Morris R et al (2022) Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials. Cancer Treat Rev 109:102429. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102429","journal-title":"Cancer Treat Rev"},{"key":"9303_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","volume":"6","author":"J Raja","year":"2018","unstructured":"Raja J, Ludwig JM, Gettinger SN et al (2018) Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 6:140. https:\/\/doi.org\/10.1186\/s40425-018-0458-z","journal-title":"J Immunother Cancer"},{"key":"9303_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/biom10020263","volume":"10","author":"DW Kim","year":"2020","unstructured":"Kim DW, Cho J-Y (2020) Recent advances in allogeneic CAR-T Cells. Biomolecules 10:263. https:\/\/doi.org\/10.3390\/biom10020263","journal-title":"Biomolecules"},{"key":"9303_CR6","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00262-020-02496-w","volume":"69","author":"Q-T Wang","year":"2020","unstructured":"Wang Q-T, Nie Y, Sun S-N et al (2020) Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol Immunother 69:1375\u20131387. https:\/\/doi.org\/10.1007\/s00262-020-02496-w","journal-title":"Cancer Immunol Immunother"},{"key":"9303_CR7","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","volume":"25","author":"E Drent","year":"2019","unstructured":"Drent E, Poels R, Ruiter R et al (2019) Combined CD28 and 4\u20131BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells. Clin Cancer Res 25:4014\u20134025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2559","journal-title":"Clin Cancer Res"},{"key":"9303_CR8","doi-asserted-by":"publisher","first-page":"11420","DOI":"10.1021\/acs.chemrev.9b00833","volume":"120","author":"W-H Li","year":"2020","unstructured":"Li W-H, Li Y-M (2020) Chemical strategies to boost cancer vaccines. Chem Rev 120:11420\u201311478. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00833","journal-title":"Chem Rev"},{"key":"9303_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.cgt.7700670","volume":"11","author":"ATC Cheuk","year":"2004","unstructured":"Cheuk ATC, Mufti GJ, Guinn B (2004) Role of 4\u20131BB:4\u20131BB ligand in cancer immunotherapy. Cancer Gene Ther 11:215\u2013226. https:\/\/doi.org\/10.1038\/sj.cgt.7700670","journal-title":"Cancer Gene Ther"},{"key":"9303_CR10","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.3390\/ijms22126210","volume":"22","author":"AG Martinez-Perez","year":"2021","unstructured":"Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R et al (2021) 4\u20131BBL as a mediator of cross-talk between innate, adaptive, and regulatory immunity against cancer. Int J Mol Sci 22:6210. https:\/\/doi.org\/10.3390\/ijms22126210","journal-title":"Int J Mol Sci"},{"key":"9303_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048463","volume":"7","author":"AK Srivastava","year":"2012","unstructured":"Srivastava AK, Sharma RK, Yolcu ES et al (2012) Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS ONE 7:e48463. https:\/\/doi.org\/10.1371\/journal.pone.0048463","journal-title":"PLoS ONE"},{"key":"9303_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omto.2020.03.003","volume":"17","author":"V Cervera-Carrascon","year":"2020","unstructured":"Cervera-Carrascon V, Quixabeira DCA, Havunen R et al (2020) Comparison of clinically relevant oncolytic virus platforms for enhancing T cell therapy of solid tumors. Mol Ther Oncolytics 17:47\u201360. https:\/\/doi.org\/10.1016\/j.omto.2020.03.003","journal-title":"Mol Ther Oncolytics"},{"key":"9303_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","volume":"33","author":"SJ Russell","year":"2018","unstructured":"Russell SJ, Barber GN (2018) Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 33:599\u2013605. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.011","journal-title":"Cancer Cell"},{"key":"9303_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010096","author":"R Garza-Morales","year":"2019","unstructured":"Garza-Morales R, Perez-Trujillo JJ, Martinez-Jaramillo E et al (2019) A DNA vaccine encoding SA-4-1BBL fused to HPV-16 E7 antigen has prophylactic and therapeutic efficacy in a cervical cancer mouse model. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11010096","journal-title":"Cancers (Basel)"},{"key":"9303_CR15","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1582-4934.2009.00934.x","volume":"14","author":"MJ Loera-Arias","year":"2010","unstructured":"Loera-Arias MJ, Mart\u00ednez-P\u00e9rez AG, Barrera-Hern\u00e1ndez A et al (2010) Targeting and retention of HPV16 E7 to the endoplasmic reticulum enhances immune tumour protection. J Cell Mol Med 14:890\u2013894. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00934.x","journal-title":"J Cell Mol Med"},{"key":"9303_CR16","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3892\/ol.2017.5635","volume":"13","author":"JJ Perez-Trujillo","year":"2017","unstructured":"Perez-Trujillo JJ, Garza-Morales R, Barron-Cantu JA et al (2017) DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect. Oncol Lett 13:1569\u20131574. https:\/\/doi.org\/10.3892\/ol.2017.5635","journal-title":"Oncol Lett"},{"key":"9303_CR17","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3390\/vaccines11081354","volume":"11","author":"AJD Silva","year":"2023","unstructured":"Silva AJD, de Moura IA, da Gama MATM et al (2023) Advancing immunotherapies for HPV-related cancers: exploring novel vaccine strategies and the influence of tumor microenvironment. Vaccines (Basel) 11:1354. https:\/\/doi.org\/10.3390\/vaccines11081354","journal-title":"Vaccines (Basel)"},{"key":"9303_CR18","doi-asserted-by":"publisher","first-page":"2912671","DOI":"10.1155\/2018\/2912671","volume":"2018","author":"MR Barros","year":"2018","unstructured":"Barros MR, de Oliveira THA, de Melo CML et al (2018) Viral modulation of TLRs and cytokines and the related immunotherapies for HPV-associated cancers. J Immunol Res 2018:2912671. https:\/\/doi.org\/10.1155\/2018\/2912671","journal-title":"J Immunol Res"},{"key":"9303_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.cyto.2019.05.011","volume":"120","author":"S Otani","year":"2019","unstructured":"Otani S, Fujii T, Kukimoto I et al (2019) Cytokine expression profiles in cervical mucus from patients with cervical cancer and its precursor lesions. Cytokine 120:210\u2013219. https:\/\/doi.org\/10.1016\/j.cyto.2019.05.011","journal-title":"Cytokine"},{"key":"9303_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020149","author":"AG Martinez-Perez","year":"2021","unstructured":"Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R et al (2021) An oncolytic adenovirus encoding SA-4\u20131BBL adjuvant fused to HPV-16 E7 antigen produces a specific antitumor effect in a cancer mouse model. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines9020149","journal-title":"Vaccines (Basel)"},{"key":"9303_CR21","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s10439-018-2107-6","volume":"46","author":"K Spyridopoulou","year":"2018","unstructured":"Spyridopoulou K, Aindelis G, Lampri E et al (2018) Improving the subcutaneous mouse tumor model by effective manipulation of magnetic nanoparticles-treated implanted cancer cells. Ann Biomed Eng 46:1975\u20131987. https:\/\/doi.org\/10.1007\/s10439-018-2107-6","journal-title":"Ann Biomed Eng"},{"key":"9303_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nri778","volume":"2","author":"SM Kaech","year":"2002","unstructured":"Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2:251\u2013262. https:\/\/doi.org\/10.1038\/nri778","journal-title":"Nat Rev Immunol"},{"key":"9303_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002603","volume":"9","author":"B-S Kim","year":"2021","unstructured":"Kim B-S, Kuen D-S, Koh C-H et al (2021) Type 17 immunity promotes the exhaustion of CD8+ T cells in cancer. J Immunother Cancer 9:e002603. https:\/\/doi.org\/10.1136\/jitc-2021-002603","journal-title":"J Immunother Cancer"},{"key":"9303_CR24","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/mt.2015.125","volume":"23","author":"A Koski","year":"2015","unstructured":"Koski A, Bramante S, Kipar A et al (2015) Biodistribution analysis of oncolytic adenoviruses in patient autopsy samples reveals vascular transduction of noninjected tumors and tissues. Mol Ther 23:1641\u20131652. https:\/\/doi.org\/10.1038\/mt.2015.125","journal-title":"Mol Ther"},{"key":"9303_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052016","volume":"11","author":"J Spayne","year":"2021","unstructured":"Spayne J, Hesketh T (2021) Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators. BMJ Open 11:e052016. https:\/\/doi.org\/10.1136\/bmjopen-2021-052016","journal-title":"BMJ Open"},{"key":"9303_CR26","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","volume":"4","author":"L Bruni","year":"2016","unstructured":"Bruni L, Diaz M, Barrionuevo-Rosas L et al (2016) Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 4:e453\u2013e463. https:\/\/doi.org\/10.1016\/S2214-109X(16)30099-7","journal-title":"Lancet Glob Health"},{"key":"9303_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N (2021) Therapeutic cancer vaccines. Nat Rev Cancer 21:360\u2013378. https:\/\/doi.org\/10.1038\/s41568-021-00346-0","journal-title":"Nat Rev Cancer"},{"key":"9303_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.hoc.2018.12.001","volume":"33","author":"PJ DeMaria","year":"2019","unstructured":"DeMaria PJ, Bilusic M (2019) Cancer vaccines. Hematol Oncol Clin North Am 33:199\u2013214. https:\/\/doi.org\/10.1016\/j.hoc.2018.12.001","journal-title":"Hematol Oncol Clin North Am"},{"key":"9303_CR29","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/jmv.25229","volume":"90","author":"L Kuryk","year":"2018","unstructured":"Kuryk L, M\u00f8ller AW, Garofalo M et al (2018) Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5\/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. J Med Virol 90:1669\u20131673. https:\/\/doi.org\/10.1002\/jmv.25229","journal-title":"J Med Virol"},{"key":"9303_CR30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/1535-7163.MCT-16-0526","volume":"16","author":"B Dai","year":"2017","unstructured":"Dai B, Roife D, Kang Y et al (2017) Preclinical evaluation of sequential combination of oncolytic adenovirus delta-24-RGD and phosphatidylserine-targeting antibody in pancreatic ductal adenocarcinoma. Mol Cancer Ther 16:662\u2013670. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0526","journal-title":"Mol Cancer Ther"},{"key":"9303_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/cgt.2014.64","volume":"22","author":"L Zhang","year":"2015","unstructured":"Zhang L, Hedjran F, Larson C et al (2015) A novel immunocompetent murine model for replicating oncolytic adenoviral therapy. Cancer Gene Ther 22:17\u201322. https:\/\/doi.org\/10.1038\/cgt.2014.64","journal-title":"Cancer Gene Ther"},{"key":"9303_CR32","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.vaccine.2018.02.070","volume":"36","author":"MJ Atherton","year":"2018","unstructured":"Atherton MJ, Stephenson KB, Nikota JK et al (2018) Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine 36:2181\u20132192. https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.070","journal-title":"Vaccine"},{"key":"9303_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14760584.2018.1434000","volume":"17","author":"WS Bowen","year":"2018","unstructured":"Bowen WS, Svrivastava AK, Batra L et al (2018) Current challenges for cancer vaccine adjuvant development. Expert Rev Vaccines 17:207\u2013215. https:\/\/doi.org\/10.1080\/14760584.2018.1434000","journal-title":"Expert Rev Vaccines"},{"key":"9303_CR34","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1158\/1535-7163.MCT-17-0071","volume":"16","author":"BFMM Porchia","year":"2017","unstructured":"Porchia BFMM, Moreno ACR, Ramos RN et al (2017) Herpes simplex virus glycoprotein D targets a specific dendritic cell subset and improves the performance of vaccines to human papillomavirus-associated tumors. Mol Cancer Ther 16:1922\u20131933. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0071","journal-title":"Mol Cancer Ther"},{"key":"9303_CR35","doi-asserted-by":"publisher","first-page":"e02616","DOI":"10.1128\/mBio.02616-20","volume":"11","author":"J Dom\u00ednguez-Andr\u00e9s","year":"2020","unstructured":"Dom\u00ednguez-Andr\u00e9s J, van Crevel R, Divangahi M, Netea MG (2020) Designing the next generation of vaccines: relevance for future pandemics. mBio 11:e02616. https:\/\/doi.org\/10.1128\/mBio.02616-20","journal-title":"mBio"},{"key":"9303_CR36","doi-asserted-by":"publisher","first-page":"6190","DOI":"10.1158\/1078-0432.CCR-17-0681","volume":"23","author":"AK Moesta","year":"2017","unstructured":"Moesta AK, Cooke K, Piasecki J et al (2017) Local delivery of OncoVEXmGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade. Clin Cancer Res 23:6190\u20136202. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0681","journal-title":"Clin Cancer Res"},{"key":"9303_CR37","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1158\/0008-5472.CAN-14-1768-A","volume":"74","author":"AK Srivastava","year":"2014","unstructured":"Srivastava AK, Dinc G, Sharma RK et al (2014) SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res 74:6441\u20136451. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1768-A","journal-title":"Cancer Res"},{"key":"9303_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","volume":"5","author":"R Garcia-Carbonero","year":"2017","unstructured":"Garcia-Carbonero R, Salazar R, Duran I et al (2017) Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer 5:71. https:\/\/doi.org\/10.1186\/s40425-017-0277-7","journal-title":"J Immunother Cancer"},{"key":"9303_CR39","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1078-0432.CCR-14-2213","volume":"21","author":"A Rodr\u00edguez-Garc\u00eda","year":"2015","unstructured":"Rodr\u00edguez-Garc\u00eda A, Gim\u00e9nez-Alejandre M, Rojas JJ et al (2015) Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin Cancer Res 21:1406\u20131418. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2213","journal-title":"Clin Cancer Res"},{"key":"9303_CR40","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","volume":"23","author":"E Eriksson","year":"2017","unstructured":"Eriksson E, Milenova I, Wenthe J et al (2017) Shaping the tumor stroma and sparking immune activation by CD40 and 4\u20131BB signaling induced by an armed oncolytic virus. Clin Cancer Res 23:5846\u20135857. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0285","journal-title":"Clin Cancer Res"},{"key":"9303_CR41","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa2206294","volume":"387","author":"LH Gutierrez Sanchez","year":"2022","unstructured":"Gutierrez Sanchez LH, Shiau H, Baker JM et al (2022) A Case series of children with acute hepatitis and human adenovirus infection. N Engl J Med 387:620\u2013630. https:\/\/doi.org\/10.1056\/NEJMoa2206294","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s11033-024-09489-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000}}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09303-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T20:36:55Z","timestamp":1738701415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09303-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9303"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09303-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11033-024-09489-3","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,9]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11033-024-09489-3","URL":"https:\/\/doi.org\/10.1007\/s11033-024-09489-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The animal study protocol was approved by the Ethics Committee of the School of Medicine, Autonomous University of Nuevo Leon (Monterrey, NL, Mexico) (protocol No. HT18-00002 approved in December 2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"408"}}